Abstract
Cardiac troponin I is one of the most specific and widely used biomarkers of myocardial infarction. Prompt recognition of elevated troponin concentrations in the blood is essential to the diagnosis and management of acute coronary syndrome (ACS). Raman spectroscopy allows for detection of the unique cTnI Raman signature based on quantitative measurement of wavelength and intensity of in elastically scattered light from molecules. For the first time in the literature, we have successfully characterized and verified the unique Raman signature of mouse cardiac troponin I protein in Bovine Serum Albumin and Human Blood Serum. Our findings potentiate technological advancement towards point-of-care testing measurement of cardiac biomarkers, which can be employed, potentially more rapid than conventional ELISA assays, in the outpatient setting and emergency departments for routine detection of cardiac troponin I elevation from patients suspected of suffering from acute coronary artery syndrome
Highlights
Detection of cardiac biomarkers in addition to characteristic symptoms and electrocardiographic abnormalities constitute current diagnostic guidelines for Acute Coronary Syndrome (ACS) [1]
This paper briefly describes the principles behind Raman Spectroscopy and our experimental approach, followed by an illustration of the unique cardiac troponin I (cTnI) Raman signature, and a discussion of the findings
For each set of data, we first identified the contribution of each regression component in explaining the variations in concentrations, and subsequently plotted the weights corresponding to the component with maximum contribution
Summary
Detection of cardiac biomarkers in addition to characteristic symptoms and electrocardiographic abnormalities constitute current diagnostic guidelines for Acute Coronary Syndrome (ACS) [1]. An elevation in cTnI concentration may warrant patient hospitalization, immediate catheter angiography, and possible therapeutic intervention, as opposed to supportive management and potential same day discharge [4]. Despite their recognition as the current gold standard [5], limitations exist in detecting elevated myocardial infarction biomarker concentrations [6] such as the need to obtain blood samples, lack of inter-laboratory standardization, and time delays that can surpass an hour for laboratory processing. Comparatively higher myocardial infarction biomarker concentrations suggest prolonged ischemia and irreversible cardiac damage
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
